Physician profile
Howard E Grill
NPI 1225027550
$3,652.19
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $652 · 2021: $1,089 · 2022: $633 · 2023: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $885.68 | 2019-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $562.21 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $413.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.66 | 2019-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $338.19 | 2019-2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals LP | $245.56 | 2019-2020 | |
| Lilly USA, LLC | $209.94 | 2020-2023 | Mounjaro |
| Amgen INC. | $123.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.64 | 2019 | |
| Abbvie INC. | $62.64 | 2021-2023 | |
| Glaxosmithkline, LLC. | $41.16 | 2022-2023 | Trelegy Ellipta |
| Allergan, INC. | $35.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.94 | 2020-2021 | |
| Esperion Therapeutics, INC. | $33.57 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.90 | 2019 | |
| Pfizer INC. | $20.55 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.74 | 2022 | |
| Shire North American Group INC | $18.55 | 2019 | |
| Hologic Sales and Service, LLC | $17.49 | 2022 | |
| Vistapharm, INC. | $13.09 | 2021 | |
| Astellas Pharma US INC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Grill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.